356 related articles for article (PubMed ID: 7405678)
21. Persistence of fluphenazine in plasma after decanoate withdrawal.
Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
[TBL] [Abstract][Full Text] [Related]
22. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
[TBL] [Abstract][Full Text] [Related]
23. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
24. [Blood serum concentration of long-acting fluphenazine in patients with various forms of schizophrenia].
Pempkowiak L; Januszkiewicz-Grabiasowa A; Góra S
Psychiatr Pol; 1979; 13(1):1-8. PubMed ID: 419224
[No Abstract] [Full Text] [Related]
25. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Odejide OA; Aderounmu AF
J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
[TBL] [Abstract][Full Text] [Related]
26. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
Miller RS; Peterson GM; McLean S; Westhead TT; Gillies P
J Clin Pharm Ther; 1995 Apr; 20(2):55-62. PubMed ID: 7650075
[TBL] [Abstract][Full Text] [Related]
27. Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.
Viala A; Hou N; Ba B; Durand A; Dufour H; D'Agostino N; Berda C; Jørgensen A
Psychopharmacology (Berl); 1984; 83(2):147-50. PubMed ID: 6146995
[TBL] [Abstract][Full Text] [Related]
28. [The plasma prolactin level under fluphenazine treatment (author's transl)].
Hinterhuber H; Platz T; Schwarz S
Wien Med Wochenschr; 1980 Sep; 130(17):566-70. PubMed ID: 7456470
[TBL] [Abstract][Full Text] [Related]
29. Dosage and side effect comparisons betweel oral and depot fluphenazine.
Schooler NR; Levine J
Psychopharmacol Bull; 1977 Jul; 13(3):29-31. PubMed ID: 329328
[No Abstract] [Full Text] [Related]
30. [Results of therapy with Lyogen-Depot in schizophrenic diseases].
Friemert K; Beier R; Vehreschild T
Psychiatr Neurol Med Psychol (Leipz); 1974 Jun; 26(6):374-7. PubMed ID: 4849639
[No Abstract] [Full Text] [Related]
31. Fluphenazine plasma levels and clinical response.
Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
J Clin Psychiatry; 1984 Sep; 45(9):370-3. PubMed ID: 6381472
[TBL] [Abstract][Full Text] [Related]
32. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.
Altamura AC; Curry SH; Montgomery S; Wiles DH
Psychopharmacology (Berl); 1985; 87(1):30-3. PubMed ID: 3933035
[TBL] [Abstract][Full Text] [Related]
33. Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate.
Wiles D; Franklin M; Dencker SJ; Johansson R; Lundin L; Malm U
Psychopharmacology (Berl); 1980; 71(2):131-6. PubMed ID: 6777812
[TBL] [Abstract][Full Text] [Related]
34. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
McCreadie RG; Dingwall JM; Wiles DH; Heykants JJ
Br J Psychiatry; 1980 Dec; 137():510-7. PubMed ID: 7011468
[TBL] [Abstract][Full Text] [Related]
35. [Clinical and ambulatory experiences with fluphenazine decanoate lyogen depot in prolonged therapy of psychiatric disorders].
Moldenhauer B
Med Welt; 1970 Jun; 25():1150-4. PubMed ID: 5512636
[No Abstract] [Full Text] [Related]
36. A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency.
Wistedt B; Jørgensen A; Wiles D
Psychopharmacology (Berl); 1982; 78(4):301-4. PubMed ID: 6818587
[TBL] [Abstract][Full Text] [Related]
37. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
MacCrimmon DJ; Saxena B; Foley P; Grof P
Neuropsychobiology; 1978; 4(6):360-5. PubMed ID: 692838
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
Wiles DH; McCreadie RG; Whitehead A
Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
[TBL] [Abstract][Full Text] [Related]
39. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
[TBL] [Abstract][Full Text] [Related]
40. Depot neuroleptic medication and serum levels by radioreceptor assay: prolactin concentration, electrocardiogram abnormalities and six-month outcome.
Turbott J; Villiger J; Hunter L
Aust N Z J Psychiatry; 1987 Sep; 21(3):327-38. PubMed ID: 3435373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
